{
  "study_metadata": {
    "design": "RCT|randomized|double-blind",
    "species": "Homo sapiens",
    "n_total": 66,
    "country": "Iran",
    "setting": "outpatient",
    "population": "type 2 diabetes patients",
    "inclusion_key": "age 20-65, ≥6 months oral hypoglycemic, no antioxidant therapy, no allergy to grapes, green tea, peanuts",
    "exclusion_key": "type 1 diabetes, pregnancy, lactation, severe heart, hepatic, renal disease",
    "mean_age": 52.0,
    "female_pct": 50.0,
    "diabetes_status": "T2D",
    "primary_outcome": "FPG"
  },
  "intervention": {
    "agent": "resveratrol",
    "form": "capsule",
    "dose_mg_per_day": 1000.0,
    "duration_weeks": 6.0,
    "cointerventions": "standard antidiabetic treatment continued"
  },
  "comparison": {
    "type": "placebo",
    "description": "placebo tablets"
  },
  "arms": [
    {
      "name": "resveratrol",
      "n": 33,
      "dose_mg_per_day": 1000.0,
      "duration_weeks": 6.0
    },
    {
      "name": "placebo",
      "n": 33,
      "dose_mg_per_day": 0.0,
      "duration_weeks": 6.0
    }
  ],
  "outcomes_raw": [
    {
      "name": "FPG",
      "timepoint_weeks": 6.0,
      "arm_name": "resveratrol",
      "baseline_mean": null,
      "baseline_sd": null,
      "followup_mean": null,
      "followup_sd": null,
      "change_mean": null,
      "change_sd": null,
      "units": "mg_dL",
      "notes": "significant decrease reported"
    },
    {
      "name": "HbA1c",
      "timepoint_weeks": 6.0,
      "arm_name": "resveratrol",
      "baseline_mean": null,
      "baseline_sd": null,
      "followup_mean": null,
      "followup_sd": null,
      "change_mean": null,
      "change_sd": null,
      "units": "%",
      "notes": "significant decrease reported"
    },
    {
      "name": "HOMA_IR",
      "timepoint_weeks": 6.0,
      "arm_name": "resveratrol",
      "baseline_mean": null,
      "baseline_sd": null,
      "followup_mean": null,
      "followup_sd": null,
      "change_mean": null,
      "change_sd": null,
      "units": "HOMA_units",
      "notes": "significant decrease reported"
    }
  ],
  "effects_by_outcome": [
    {
      "name": "FPG",
      "type": null,
      "timepoint_weeks": 6.0,
      "estimate": null,
      "ci_low": null,
      "ci_high": null,
      "p_value": null,
      "adjusted": false,
      "model_notes": null
    },
    {
      "name": "HbA1c",
      "type": null,
      "timepoint_weeks": 6.0,
      "estimate": null,
      "ci_low": null,
      "ci_high": null,
      "p_value": null,
      "adjusted": false,
      "model_notes": null
    },
    {
      "name": "HOMA_IR",
      "type": null,
      "timepoint_weeks": 6.0,
      "estimate": null,
      "ci_low": null,
      "ci_high": null,
      "p_value": null,
      "adjusted": false,
      "model_notes": null
    }
  ],
  "risk_of_bias": {
    "randomization_process": null,
    "deviations_from_intended": null,
    "missing_outcome_data": null,
    "measurement_of_outcome": null,
    "selection_of_reported_result": null,
    "overall": null
  },
  "effect": {
    "type": null,
    "estimate": null,
    "ci_low": null,
    "ci_high": null,
    "p_value": null
  },
  "where_found": [
    {
      "section": "abstract",
      "page": null
    },
    {
      "section": "methods",
      "page": null
    },
    {
      "section": "results",
      "page": null
    }
  ],
  "evidence": [
    {
      "section": "abstract",
      "page": null,
      "snippet": "The objective of this study was to examine the effectiveness of resveratrol in lowering blood glucose in the presence of standard antidiabetic treatment in patients with type 2 diabetes, in a randomized placebo-controlled double-blinded parallel clinical trial."
    },
    {
      "section": "methods",
      "page": null,
      "snippet": "The patients in the intervention group received 500 mg, twice a day (a total of 1 g/day) of resveratrol capsules for a period of 45 days. The control group received 500 mg twice daily of placebo capsules for the same period of time."
    },
    {
      "section": "results",
      "page": null,
      "snippet": "Resveratrol treatment significantly decreased fasting blood glucose, haemoglobin A1c, insulin, and insulin resistance, while HDL was significantly increased, when compared to their baseline levels."
    }
  ],
  "missing_fields": [
    "outcomes_raw.baseline_mean",
    "outcomes_raw.baseline_sd",
    "outcomes_raw.followup_mean",
    "outcomes_raw.followup_sd",
    "outcomes_raw.change_mean",
    "outcomes_raw.change_sd",
    "effects_by_outcome.estimate",
    "effects_by_outcome.ci_low",
    "effects_by_outcome.ci_high",
    "effects_by_outcome.p_value",
    "risk_of_bias.randomization_process",
    "risk_of_bias.deviations_from_intended",
    "risk_of_bias.missing_outcome_data",
    "risk_of_bias.measurement_of_outcome",
    "risk_of_bias.selection_of_reported_result",
    "risk_of_bias.overall"
  ],
  "confidence": 0.6,
  "comment": "Data limited; numeric outcomes missing",
  "comment_detailed": "I searched the abstract, methods, and results sections for numeric values of fasting plasma glucose, HbA1c, and HOMA‑IR. The article reports significant decreases but does not provide means, SDs, or effect sizes. Therefore, baseline and follow‑up statistics, change values, and effect estimates are set to null. Design, population, intervention details, and comparison are extracted from the text. Risk‑of‑bias items are unknown due to lack of reporting. Additional information would be available in full tables or supplementary material."
}